Psychiatry

Back to articles

Augmentation with a second-generation antipsychotic is effective in major depressive disorder

KEY POINT

Addition of aripiprazole for patients with major depressive disorder (MDD) who were unresponsive to at least one antidepressant resulted in higher remission rates at 12 weeks compared with switching to a different antidepressant (i.e., bupropion sustained release) or adding bupropion sustained release to the current regimen, according to results from the VAST-D trial published in JAMA.